<DOC>
	<DOC>NCT01902472</DOC>
	<brief_summary>This study will evaluate HIV-1 RNA and the presence or absence of resistance at baseline and following seroconversion, assess the frequency of HIV-1 screening and screening method(s) used for evaluation of seroconverters, and collect information regarding whether the seroconverter experienced signs and symptoms of acute HIV-1 infection prior to or at the time of seroconversion.</brief_summary>
	<brief_title>A Prospective, Observational Study of Individuals Who Seroconvert While Taking Truvada® for Pre-Exposure Prophylaxis (PrEP)</brief_title>
	<detailed_description />
	<mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Participant in a FTC/TDF PrEP demonstration project or FTC/TDF for PrEP clinical study HIV1 negative adults (any sex/gender, including transgender) ≥ 18 years of age at time of enrollment in the demonstration project or clinical study. Evidence of seroconversion while receiving FTC/TDF for PrEP This is an observational nested study and will monitor all reported seroconversions without intervention/exclusion.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Truvada</keyword>
	<keyword>FTC/TDF</keyword>
	<keyword>Pre-exposure prophylaxy</keyword>
	<keyword>PrEP</keyword>
	<keyword>Resistance</keyword>
</DOC>